
Oramed Pharmaceuticals Inc
NASDAQ:ORMP

Intrinsic Value
The intrinsic value of one
ORMP
stock under the Base Case scenario is
1.95
USD.
Compared to the current market price of 2.13 USD,
Oramed Pharmaceuticals Inc
is
Overvalued by 8%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Oramed Pharmaceuticals Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Oramed Pharmaceuticals Inc
Balance Sheet Decomposition
Oramed Pharmaceuticals Inc
Current Assets | 131.5m |
Cash & Short-Term Investments | 130.6m |
Other Current Assets | 832k |
Non-Current Assets | 16.1m |
Long-Term Investments | 9.5m |
PP&E | 1m |
Other Non-Current Assets | 5.5m |
Free Cash Flow Analysis
Oramed Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Oramed Pharmaceuticals Inc
Revenue
|
2m
USD
|
Cost of Revenue
|
-2m
USD
|
Gross Profit
|
13k
USD
|
Operating Expenses
|
-14.3m
USD
|
Operating Income
|
-14.3m
USD
|
Other Expenses
|
-13.9m
USD
|
Net Income
|
-28.2m
USD
|
ORMP Profitability Score
Profitability Due Diligence
Oramed Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Score
Oramed Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ORMP Solvency Score
Solvency Due Diligence
Oramed Pharmaceuticals Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Score
Oramed Pharmaceuticals Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ORMP Price Targets Summary
Oramed Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
ORMP
is 3.32 USD
with a low forecast of 3.28 USD and a high forecast of 3.41 USD.
Dividends
Current shareholder yield for ORMP is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ORMP
stock under the Base Case scenario is
1.95
USD.
Compared to the current market price of 2.13 USD,
Oramed Pharmaceuticals Inc
is
Overvalued by 8%.